Relmada Therapeutics (RLMD) Accumulated Depreciation & Amortization (2015 - 2021)
Relmada Therapeutics (RLMD) reported Accumulated Depreciation & Amortization of $1258.0 for Q3 2021, down 57.05% year-over-year from $2929.0 in Q3 2020, and down 99.9% on a QoQ basis from $1.3 million in Q2 2021.
Relmada Therapeutics (RLMD) has 7 years of Accumulated Depreciation & Amortization data on file, last reported at $1258.0 in Q3 2021.
- Quarterly Accumulated Depreciation & Amortization fell 57.05% year-over-year to $1258.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $1258.0 (down 57.05% YoY) and the FY2020 annual result came in at $15442.0, up 32.1% from the prior year.
- Accumulated Depreciation & Amortization fell to $1258.0 in Q3 2021 per RLMD's latest filing, from $1.3 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $2.1 million in Q2 2020 and bottomed at $1258.0 in Q3 2021.
- The 5-year median for Accumulated Depreciation & Amortization is $8402.0 (2019), against an average of $192003.9.
- The widest annual swing landed in 2018, when Accumulated Depreciation & Amortization plunged 97.16%; it then jumped 22028.56% in 2020.
- Tracing RLMD's Accumulated Depreciation & Amortization over 5 years: stood at $3124.0 in 2017, then jumped by 134.51% to $7326.0 in 2018, then soared by 59.57% to $11690.0 in 2019, then surged by 32.1% to $15442.0 in 2020, then tumbled by 91.85% to $1258.0 in 2021.
- Per Business Quant, the three latest RLMD Accumulated Depreciation & Amortization figures stand at $1258.0 (Q3 2021), $1.3 million (Q2 2021), and $16248.0 (Q1 2021).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 1,258.00 |
| Sep 30, 2021 | 1,258.00 |
| Jun 30, 2021 | 1.30 Mn |
| Jun 30, 2021 | 1.30 Mn |
| Mar 31, 2021 | 16,248.00 |
| Mar 31, 2021 | 16,248.00 |
| Dec 31, 2020 | 15,442.00 |
| Dec 31, 2020 | 15,442.00 |
| Sep 30, 2020 | 2,929.00 |
| Sep 30, 2020 | 2,929.00 |
| Jun 30, 2020 | 2.10 Mn |
| Jun 30, 2020 | 2.10 Mn |
| Mar 31, 2020 | 12,736.00 |
| Mar 31, 2020 | 12,736.00 |
| Dec 31, 2019 | 11,690.00 |
| Dec 31, 2019 | 11,690.00 |
| Sep 30, 2019 | 10,590.00 |
| Sep 30, 2019 | 10,590.00 |
| Jun 30, 2019 | 9,490.00 |
| Jun 30, 2019 | 9,490.00 |
| Mar 31, 2019 | 8,402.00 |
| Mar 31, 2019 | 8,402.00 |
| Dec 31, 2018 | 7,326.00 |
| Dec 31, 2018 | 7,326.00 |
| Sep 30, 2018 | 6,024.00 |
| Sep 30, 2018 | 6,024.00 |
| Jun 30, 2018 | 4,620.00 |
| Jun 30, 2018 | 4,620.00 |
| Mar 31, 2018 | 3,692.00 |
| Mar 31, 2018 | 3,692.00 |
| Dec 31, 2017 | 3,124.00 |
| Dec 31, 2017 | 3,124.00 |
| Sep 30, 2017 | 2,542.00 |
| Sep 30, 2017 | 2,542.00 |
| Jun 30, 2017 | 1,985.00 |
| Jun 30, 2017 | 1,985.00 |
| Mar 31, 2017 | 129,976.00 |
| Mar 31, 2017 | 129,976.00 |
| Dec 31, 2016 | 106,635.00 |
| Dec 31, 2016 | 106,635.00 |
| Sep 30, 2016 | 83,088.00 |
| Sep 30, 2016 | 83,088.00 |
| Jun 30, 2016 | 63,752.00 |
| Jun 30, 2016 | 63,752.00 |
| Mar 31, 2016 | 43,954.00 |
| Mar 31, 2016 | 43,954.00 |
| Dec 31, 2015 | 16,360.00 |
| Dec 31, 2015 | 16,360.00 |
| Jun 30, 2015 | 10,389.00 |
| Jun 30, 2015 | 10,389.00 |